Nature Communications (Feb 2022)

Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies

  • Daniel Re,
  • Barbara Seitz-Polski,
  • Vesna Brglez,
  • Michel Carles,
  • Daisy Graça,
  • Sylvia Benzaken,
  • Stéphane Liguori,
  • Khaled Zahreddine,
  • Margaux Delforge,
  • Béatrice Bailly-Maitre,
  • Benjamin Verrière,
  • Emmanuel Chamorey,
  • Jérôme Barrière

DOI
https://doi.org/10.1038/s41467-022-28578-0
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 9

Abstract

Read online

Vaccination is effective in preventing severe COVID-19 symptoms. Here the authors monitor patients with hematopoietic malignancy to find the third dose of the mRNA vaccine, BNT162b2, only boosts the humoral immunity in those showing responses to 2nd dose vaccination but can induce an independent T-cell response in a fraction of seronegative patients.